Efficacy of liposome-encapsulated mepivacaine for infiltrative anesthesia in volunteers

Autor(es)

Tofoli, Giovana R. ^{[1, 2]} ; Cereda, Cintia M. S. ^[1] ; Groppo, Francisco C. ^[3] ; Volpato, Maria C. ^[3] ; Franz-Montan, Michelle ^[1] ; Ranali, Jose ^[3] ; de Araujo, Daniele Ribeiro ^{[4, 1]} ; de Paula, Eneida ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Dept Biochem, Inst Biol, Sao Paulo - Brazil

^[2] Univ Sao Francisco, UNIFAG, Clin Pharmacol & Gastroenterol Unit, Sao Paulo - Brazil

^[3] Univ Estadual Campinas, Dept Physiol Sci, Piracicaba Dent Sch, Sao Paulo - Brazil

^[4] Fed Univ ABC, Human & Nat Sci Ctr, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Liposome Research; v. 21, n. 1, p. 88-94, MAR 2011.
• Citações Web of Science: 16

Resumo

This blinded crossover study evaluated the efficacy and pain sensitivity evoked by a previously reported liposome-encapsulated mepivacaine formulation (Araujo et al., 2004). Thirty healthy volunteers received an intraoral injection (1.8 mL), at four different sessions, of the following formulations:2% mepivacaine with 1:100,000 epinephrine (MVC(2%EPI)), 3% mepivacaine (MVC(3%)), and 2 and 3% liposome-encapsulated mepivacaine (MVC(2%LUV) and MVC(3%LUV)). Latency period and duration of anesthesia were assessed by an electrical pulp tester and injection discomfort by a visual analog scale (VAS). Data were analyzed with Tukey-Kramer and Friedman tests (P < 0.05). No significant difference was found regarding latency period (in minutes) among the formulations (P > 0.05). The duration of anesthesia after the injection of MVC(3%LUV) was higher than the one obtained after the infiltration of MVC(2%LUV) and of MVC(3%) (P < 0.05). However, the duration of anesthesia obtained with MVC(3%) did not differ from the one obtained with MVC(2%LUV) (P > 0.05). MVC(3%LUV) showed lower VAS median values than MVC(2%EPI) (P < 0.05), and there were no significant differences among the others formulations. Liposome-encapsulated 3% mepivacaine showed longer duration of anesthesia, in comparison to the commercial formulation of MVC(3%). MVC(2%LUV) was able to produce a similar duration of anesthesia as the 3% commercial formulation, despite the 50% decrease in the anesthetic concentration. Thus, the encapsulation of mepivacaine increased the duration of anesthesia and reduced the injection discomfort caused by vasoconstrictor-associated formulations in healthy volunteers. (AU)

• Processo FAPESP: 06/00121-9 - Novas formulações de anestésicos locais de liberação controlada: do desenvolvimento ao teste clínico odontológico
• Beneficiário: Eneida de Paula
• Modalidade de apoio: Auxílio à Pesquisa - Temático